SARS CoV 2 News and Research

RSS

Uracil point mutations found in SARS-CoV-2 variants alter innate immune responses

Tohoku University scientists have found that human editing enzymes are likely behind a type of mutation in the COVID-19 virus that stimulates the release of pro-inflammatory molecules called cytokines by immune cells in the body.

11 Nov 2020

Host genetic "super-variants" may increase COVID-19 death risk

Researchers at Yale University have identified genetic variants among people of white British ancestry that may increase the risk of dying from coronavirus disease 2019 (COVID-19) – the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 Nov 2020

Rheumatoid arthritis may increase risk of dying from COVID-19

Researchers in New Zealand and Australia have conducted a study showing that people with rheumatoid arthritis may be at an increased risk of death if they develop coronavirus disease 2019 (COVID-19) after becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 Nov 2020

Low prevalence of SARS-CoV-2 specific antibodies in Lubbock, Texas

A recent study published in the Journal of Primary Care and Community Health has assessed the prevalence of antibodies developed specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in front-line workers in Lubbock, Texas. According to the study findings, immunoglobulin G (IgG)-specific anti-SARS-CoV-2 antibodies have been detected in only 0.73% of the participants.

11 Nov 2020

Research tracks humoral immunity response over eight months post COVID-19 infection

Researchers from Chongqing Medical University have tried to answer one of the burning questions regarding the longevity of immune response to coronavirus disease 2019 (COVID-19): How long does immunity last after infection? Their study looked at the lasting effects and continued immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over eight months after recovery from the infection.

11 Nov 2020

Nafamostat mesylate initially reduces SARS-CoV-2 viral loads in hamsters, study finds

Researchers have found that nafamostat mesylate, when injected in the nasal cavity of Syrian hamsters, can decrease initial SARS-CoV-2 viral loads in their nose. However, this effect was temporary and further testing is required to determine clinically significant effects. The research group's findings are available on the preprint server bioRxiv*.

11 Nov 2020

Study identifies genetic risk for fatal blood clots in IBD patients

Blood clots are the biggest cause of death in patients with inflammatory bowel disease (IBD) ─ ulcerative colitis or Crohn's disease. In a retrospective study recently published in the journal Gastroenterology, Cedars-Sinai investigators found that a combination of rare and common genetic variants in some IBD patients significantly increased their risk of developing clot-causing thromboembolic diseases.

11 Nov 2020

New study highlights the burden of post-COVID fatigue

More than half of people with acute COVID-19 infection continue to have persistent fatigue 10 weeks after their initial illness, according to a new study published November 9 in the open-access journal PLOS ONE by Liam Townsend of Trinity College Dublin, Ireland and colleagues.

11 Nov 2020

Researchers use machine learning algorithm to identify common respiratory pathogens

The ongoing global pandemic has created an urgent need for rapid tests that can diagnose the presence of the SARS-CoV-2 virus, the pathogen that causes COVID-19, and distinguish it from other respiratory viruses.

11 Nov 2020

How SARS-CoV-2 blocks immune response

An international research team has confirmed the mechanism by which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Their article titled, “SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling,” is published in the journal Proceedings of the National Academy of Sciences.

11 Nov 2020

Parents normalize children's symptoms to discount COVID-19, study finds

A new study by researchers from King's College London explores parental perceptions of COVID-19-like symptoms in their children and attitudes towards isolating them from others in the household when they are feeling unwell.

10 Nov 2020

Nearly 1 in 5 COVID-19 survivors develop mental illness within 90 days

A new study has found that people who have COVID-19 may have an increased risk of being diagnosed with a psychiatric disorder, including anxiety and depression, within 90 days after diagnosis.

10 Nov 2020

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

A new study describes two promising small molecules that inhibit a host cell factor, called nucleotide binding oligomerization domain-containing protein 2 (NOD2), that inhibits the replication and spread of many arboviruses. This could lead to the development of broad-spectrum antivirals. The study's findings have been published on the preprint server bioRxiv*.

10 Nov 2020

COVID-19-associated pulmonary aspergillosis caused by aspergillus fumigatus

A new study published on the preprint server bioRxiv in November 2020 discusses the characteristics of COVID-19 associated pulmonary aspergillosis (CAPA).

10 Nov 2020

Researchers uncover new 'hidden' gene in SARS-CoV-2

Researchers have discovered a new "hidden" gene in SARS-CoV-2--the virus that causes COVID-19--that may have contributed to its unique biology and pandemic potential.

10 Nov 2020

Study finds diabetes epidemic among Xavante indigenous community in Central Brazil

The Xavante, one of the indigenous communities most vulnerable to SARS-CoV-2 in Brazil, are suffering from an epidemic of diabetes, a "silent" disease considered a risk factor for severe COVID-19.

10 Nov 2020

Lessons from USS Theodore Roosevelt on limiting shipborne COVID-19 outbreaks

A new study published on the preprint server medRxiv* in November 2020 discusses such a scenario in terms of various possible approaches. It suggests that a viable strategy could be evacuating everyone from the ship and extensive surveillance testing.

10 Nov 2020

SARS-CoV-2 RNA genome structure reveals potential targets for development of drugs

The SARS-CoV-2 coronavirus RNA genome structure was studied in detail by researchers from the University of Groningen, the International Institute of Molecular and Cell Biology in Warsaw, and Leiden University.

10 Nov 2020

SARS-CoV-2 spike glycoprotein optimized for conditions present in human airways

Researchers from Belgium and Germany demonstrated how the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is fine-tuned towards the temperature and protease conditions of the human airways, which in turn enhances viral transmission and subsequent pathology. Their study is available on the bioRxiv* preprint server.

10 Nov 2020

Endothelial cells resistant to SARS-CoV-2 infection

A team of scientists from Imperial College London has conducted a series of in vitro studies to investigate the susceptibility of endothelial cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative pathogen of coronavirus disease 2019 (COVID-19).

10 Nov 2020